Knight Therapeutics Q2 EPS $(0.03) Misses $0.01 Estimate, Sales $144.212M Beat $124.966M Estimate
Knight Therapeutics (TSX:GUD) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $0.01 by 400 percent. This is a 76.92 percent increase over losses of $(0.13) per share from
Read original at benzinga